PCM
CRSP icon

Palisade Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Palisade Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,550
Closed -$246K – 451
2018
Q3 		$246K Buy
+5,550
New +$291K 0.01% 438

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Palisade Capital Management's CRSP Position: Q4 2018 in Review

Palisade Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2018, closing a stake of 5,550 shares — an estimated $246K sold.

Palisade Capital Management first reported a position in CRSP in Q3 2018 and held it in 1 quarter. The position peaked at $246K in Q3 2018. 155 funds tracked by Wall St. Rank hold CRSP as of Q4 2018.

  • Palisade Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Palisade Capital Management sold 5,550 CRISPR Therapeutics shares in Q4 2018, an estimated $246K.
  • Palisade Capital Management first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 1 quarter.
  • Palisade Capital Management's CRISPR Therapeutics position peaked at $246K in Q3 2018.
  • 155 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2018.

Based on Palisade Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.